Expression of p16INK4A but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma

Cancer

Volumn 116, Issue 22, 2010, Pages 5179-5187

  Chang, Daniel T ^a   Chapman, Christopher H ^a   Norton, Jeffrey A ^a   Visser, Brendan ^a   Fisher, George A ^a   Kunz, Pamela ^a   Ford, James M ^a   Koong, Albert C ^a   Pai, Reetesh K ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cyclin dependent kinase inhibitor; p16; pancreas cancer; tissue microarray

Indexed keywords

CARBONATE DEHYDRATASE IX; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIHYDROFOLATE REDUCTASE; DNA; K RAS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; POINT MUTATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL HYPOXIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TETRAHYDROFOLATE DEHYDROGENASE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78449285473     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25481     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ., Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Adsay NV, Basturk O, Cheng JD, Andea AA., Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin Radiat Oncol. 2005; 15: 254-264.
3. Maitra A, Kern SE, Hruban RH., Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006; 20: 211-226.
4. Brown JM, Giaccia AJ., The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998: 1408-1416.
5. Yun Z, Giaccia AJ., Tumor deprivation of oxygen and tumor suppressor gene function. Methods Mol Biol. 2003: 485-504.
6. Cairns RA., Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy. Proc Natl Acad Sci U S A. 2007; 104: 9445-9450.
7. Brizel DM, Scully SP, Harrelson JM, et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 1996; 56: 5347-5350.
8. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002; 20: 680-687.
9. Nordsmark M, Overgaard J., Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol. 2004; 43: 396-403.
10. Hockel M, Vaupel P., Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001; 93: 266-276.
11. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW., Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1997; 38: 285-289.
12. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; 12: 1507-1514.
13. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56: 4509-4515.
14. Koong AC, Mehta VK, Le QT, et al. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys. 2000; 48: 919-922.
15. Le QT, Kong C, Lavori PW, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007; 69: 167-175.
16. Naka T, Kobayashi M, Ashida K, Toyota N, Kaneko T, Kaibara N., Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int J Oncol. 1998; 12: 1111-1116.
17. Kloppel G, Hruban RH, Longnecker DS, Adler G, Kern SE, Partanen TJ., Ductal Adenocarcinoma of the Pancreas. Lyon, France: IARC Press; 2000.
18. Nocito A, Kononen J, Kallioniemi OP, Sauter G., Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer. 2001; 94: 1-5.
19. Swinson DE, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003; 21: 473-482.
20. Cui Y, Tian M, Zong M, et al. Proteomic analysis of pancreatic ductal adenocarcinoma compared with normal adjacent pancreatic tissue and pancreatic benign cystadenoma. Pancreatology. 2009; 9: 89-98.
21. Cui Y, Wu J, Zong M, et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer. 2009; 124: 1614-1621.
22. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
23. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349: 247-257.
24. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994; 8: 27-32.
25. Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ., Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosomes Cancer. 1995; 14: 189-195.
26. Hruban RH, Goggins M, Parsons J, Kern SE., Progression model for pancreatic cancer. Clin Cancer Res. 2000; 6: 2969-2972.
27. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003; 17: 3112-3126.
28. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006; 103: 5947-5952.
29. Wilentz RE, Geradts J, Maynard R, et al. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res. 1998; 58: 4740-4744.
30. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000; 60: 1835-1839.
31. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997; 57: 1731-1734.
32. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997; 57: 3126-3130.
33. INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of 4 commercial antibodies. Appl Immunohistochem Mol Morphol. 2000; 8: 71-79.
34. Lynch HT, Deters CA, Lynch JF, Brand RE., Familial pancreatic carcinoma in Jews. Fam Cancer. 2004; 3: 233-240.
35. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002; 347: 1566-1575.
36. Skalicky DA, Kench JG, Segara D, et al. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1941-1947.
37. Kawesha A, Ghaneh P, Andren-Sandberg A, et al. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2000; 89: 469-474.
38. Biankin AV, Morey AL, Lee CS, et al. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol. 2002; 20: 4531-4542.
39. Hu YX, Watanabe H, Ohtsubo K, et al. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin Cancer Res. 1997; 3: 1473-1477.
40. INK4a, p53, MDM2, an Rb. Ann Surg. 2002; 235: 51-59.
41. Jeong J, Park YN, Park JS, Yoon DS, Chi HS, Kim BR., Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J. 2005; 46: 519-525.
42. Salek C, Minarikova P, Benesova L, et al. Mutation status of K-ras, p53 and allelic losses at 9p and 18q are not prognostic markers in patients with pancreatic cancer. Anticancer Res. 2009; 29: 1803-1810.
43. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009; 15: 4674-4679.
44. Evans SM, Koch CJ., Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195: 1-16.
45. Peralta-Leal A, Rodriguez MI, Oliver FJ., Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. Clin Transl Oncol. 2008; 10: 318-323.
46. Comen EA, Robson M., Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park). 2010; 24: 55-62.